JP2018021051A5 - - Google Patents

Download PDF

Info

Publication number
JP2018021051A5
JP2018021051A5 JP2017160336A JP2017160336A JP2018021051A5 JP 2018021051 A5 JP2018021051 A5 JP 2018021051A5 JP 2017160336 A JP2017160336 A JP 2017160336A JP 2017160336 A JP2017160336 A JP 2017160336A JP 2018021051 A5 JP2018021051 A5 JP 2018021051A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017160336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018021051A (ja
JP6393380B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018021051A publication Critical patent/JP2018021051A/ja
Publication of JP2018021051A5 publication Critical patent/JP2018021051A5/ja
Application granted granted Critical
Publication of JP6393380B2 publication Critical patent/JP6393380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017160336A 2013-11-11 2017-08-23 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン Active JP6393380B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11
US61/902,544 2013-11-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016528882A Division JP6234571B2 (ja) 2013-11-11 2014-11-06 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018000710A Division JP2018070658A (ja) 2013-11-11 2018-01-05 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン

Publications (3)

Publication Number Publication Date
JP2018021051A JP2018021051A (ja) 2018-02-08
JP2018021051A5 true JP2018021051A5 (enExample) 2018-03-22
JP6393380B2 JP6393380B2 (ja) 2018-09-19

Family

ID=52003049

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2016528882A Active JP6234571B2 (ja) 2013-11-11 2014-11-06 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2017160336A Active JP6393380B2 (ja) 2013-11-11 2017-08-23 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2018000710A Withdrawn JP2018070658A (ja) 2013-11-11 2018-01-05 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2019222179A Active JP7054394B2 (ja) 2013-11-11 2019-12-09 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2020193294A Active JP7247155B2 (ja) 2013-11-11 2020-11-20 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2022063956A Withdrawn JP2022088661A (ja) 2013-11-11 2022-04-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2024006714A Withdrawn JP2024041986A (ja) 2013-11-11 2024-01-19 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2025188200A Pending JP2026027391A (ja) 2013-11-11 2025-11-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016528882A Active JP6234571B2 (ja) 2013-11-11 2014-11-06 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2018000710A Withdrawn JP2018070658A (ja) 2013-11-11 2018-01-05 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2019222179A Active JP7054394B2 (ja) 2013-11-11 2019-12-09 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2020193294A Active JP7247155B2 (ja) 2013-11-11 2020-11-20 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2022063956A Withdrawn JP2022088661A (ja) 2013-11-11 2022-04-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2024006714A Withdrawn JP2024041986A (ja) 2013-11-11 2024-01-19 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2025188200A Pending JP2026027391A (ja) 2013-11-11 2025-11-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン

Country Status (36)

Country Link
US (5) US9388208B2 (enExample)
EP (3) EP3505173B1 (enExample)
JP (8) JP6234571B2 (enExample)
KR (4) KR102355881B1 (enExample)
CN (3) CN110003215B (enExample)
AP (1) AP2016009186A0 (enExample)
AU (5) AU2014346665A1 (enExample)
BR (1) BR112016010261B1 (enExample)
CA (1) CA2928674C (enExample)
CL (1) CL2016001120A1 (enExample)
CR (1) CR20160220A (enExample)
CU (1) CU20160065A7 (enExample)
CY (2) CY1121948T1 (enExample)
DK (2) DK3505173T3 (enExample)
DO (1) DOP2016000107A (enExample)
EA (2) EA039734B1 (enExample)
ES (2) ES2743619T3 (enExample)
GT (1) GT201600086A (enExample)
HR (2) HRP20191303T1 (enExample)
HU (2) HUE044960T2 (enExample)
IL (1) IL245324B (enExample)
LT (2) LT3068405T (enExample)
MD (1) MD4596C1 (enExample)
MX (2) MX376186B (enExample)
MY (2) MY182986A (enExample)
NZ (1) NZ719592A (enExample)
PE (1) PE20160670A1 (enExample)
PH (1) PH12016500867A1 (enExample)
PL (2) PL3068405T3 (enExample)
PT (2) PT3505173T (enExample)
SG (1) SG11201603427XA (enExample)
SI (2) SI3068405T1 (enExample)
TR (1) TR201910961T4 (enExample)
UA (1) UA119050C2 (enExample)
WO (1) WO2015069939A1 (enExample)
ZA (1) ZA201603123B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599404A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
SG10201810361TA (en) 2014-09-26 2018-12-28 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
TWI698444B (zh) * 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
DK3349758T3 (da) 2015-09-16 2022-06-13 Gilead Sciences Inc Fremgangsmåder til behandling af arenaviridae-virusinfektioner
JP6768796B2 (ja) * 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
US10745427B2 (en) 2016-03-09 2020-08-18 Janssen Biopharma, Inc. Acyclic antivirals
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
WO2019053696A1 (en) * 2017-09-18 2019-03-21 Alios Biopharma, Inc. SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
WO2020232194A1 (en) * 2019-05-14 2020-11-19 The Regents Of The University Of Michigan Methods for glycosylation
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
LT4192839T (lt) 2020-08-06 2025-11-25 Remdesiviro tarpiniai junginiai
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物及びその使用
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TWI925033B (zh) * 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
CN113880846B (zh) * 2020-12-31 2022-10-14 山东诚汇双达药业有限公司 一种7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的制备方法
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) * 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US20230382940A1 (en) * 2022-03-03 2023-11-30 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN118843629A (zh) 2022-03-03 2024-10-25 吉利德科学公司 抗病毒化合物及其制备和使用方法
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2025049699A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
KR20260079626A (ko) 2023-09-28 2026-06-02 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
NZ598927A (en) * 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
DK2155758T3 (da) * 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
ATE515861T1 (de) 2007-07-25 2011-07-15 Nokia Siemens Networks Oy Verfahren zur adressierung von ethernetströmen mit strukturierter gpon-gem-port-id
PL2280973T3 (pl) 2008-04-23 2013-05-31 Gilead Sciences Inc Analogi karba-nukleozydowe do leczenia przeciwwirusowego
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
NZ599404A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
DK2480552T3 (en) 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
US8455451B2 (en) * 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EA025311B1 (ru) * 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
PT2595980E (pt) * 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之2’-氟取代之碳-核苷類似物
SG188223A1 (en) * 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療c型肝炎病毒(hcv)之方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
KR102072041B1 (ko) * 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
NZ629996A (en) * 2012-03-13 2016-10-28 Gilead Sciences Inc 2’- substituted carba-nucleoside analogs for antiviral treatment
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Similar Documents

Publication Publication Date Title
JP2017523169A5 (enExample)
JP2015024998A5 (enExample)
JP2016536286A5 (enExample)
JP2017531038A5 (enExample)
JP2018537535A5 (enExample)
JP2019505529A5 (enExample)
JP2006182786A5 (enExample)
JP2016525102A5 (enExample)
JP2019516739A5 (enExample)
JP2012525393A5 (enExample)
JP2018524298A5 (enExample)
JP2009504763A5 (enExample)
JP2013534248A5 (enExample)
JP2012504133A5 (enExample)
JP2016515561A5 (enExample)
JP2016518437A5 (enExample)
JP2009535352A5 (enExample)
JP2013542261A5 (enExample)
JP2013508279A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2020097577A5 (enExample)
JP2015534562A5 (enExample)
JP2016522254A5 (enExample)
JP2017533930A5 (enExample)
JP2014505107A5 (enExample)